Amidst a flurry of documentation about diminished use of health services during the COVID-19 pandemic, the cohort study by Doan et al 1 in this issue of JAMA Network Open analyzed the trajectory of national breast cancer screening and lung cancer screening from the COVID-19 pandemic onset through April 2022. Lower-than-expected cancer screening rates were noted for both lung cancer and breast cancer during the late 2020 national COVID-19 infection rate surge and the Delta and Omicron waves in 2021 and 2022. By recognizing this persistent depression in breast cancer screening and lung cancer screening, Doan et al 1 highlighted missed opportunities to improve cancer stage at diagnosis and survival afforded by screening.Doan et al 1 used national Medicare data to support analyses of mammography to screen for breast cancer and low-dose computerized tomography to screen for lung cancer among eligible beneficiaries, accounting for age, sex, race, ethnicity, comorbidities, Medicaid enrollment, primary care physician relationship, and educational attainment. In light of widely-reported, substantial disparities in screening, this recent, national data set provides opportunities to report on disparities in the use of these cancer screening services. This Invited Commentary considers the measurement of COVID-19's effect on established screening processes and opportunities for improving screening by engaging the individuals and communities most impacted by these depressed screening rates.